Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has shared an announcement.
CARsgen Therapeutics Holdings Ltd. has announced the preliminary results of its BCMA-targeting allogeneic CAR T-cell product candidate, CT0596, at the 67th Annual Congress of the American Society of Hematology. The results, presented as a poster, indicate favorable tolerability and encouraging efficacy signals in patients with relapsed/refractory multiple myeloma. The company plans further investigations into additional plasma cell malignancies and autoimmune diseases, with an IND application anticipated in the second half of 2025. This development highlights CARsgen’s ongoing efforts to enhance its industry positioning by expanding its product pipeline and addressing challenges in existing CAR T-cell therapies.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The company has developed comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen’s mission is to become a global leader in biopharmaceuticals by providing innovative and differentiated cell therapies to patients worldwide.
Average Trading Volume: 1,960,477
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.51B
Learn more about 2171 stock on TipRanks’ Stock Analysis page.